Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Modern principles and prospects for drug therapy of interstitial lung diseases in children
https://doi.org/10.21508/1027-4065-2022-67-3-18-22
Abstract
The article discusses the principles of therapy and prospects for the treatment of interstitial lung diseases in children. Many of interstitial lung diseases occur with progressive fibrosis, so the use of new antifibrotic drugs is especially relevant now. These drugs include pirfenidone and nintedanib. Therapy of interstitial lung diseases using antifibrotic drugs in children is a promising new direction.
About the Authors
N. S. Lev
Veltischev Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
Yu. L. Mizernitsky
Veltischev Research and Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Bush A., Cunningham S., de Blic J., Barbato A., Clement A., Epaud R. et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax 2015; 70(11): 1078–1084. DOI: 10.1136/thoraxjnl-2015-207349
2. Saddi V., Beggs S., Bennetts B. Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade’s experience. Orphanet J Rare Dis 2017; 12: 133. DOI: 10.1186/s13023-017-0637-x
3. Lev N.S., Mizernitskiy Yu.L. Clinical vaziants of interstitial lang diseases in childhood M.: Medpraktika-M, 2021; 368 p. (in Russ.)
4. Avdeev S.N., Chikina S.Yu., Tyurin I.E., Belevskiy A.S., Terpigorev S.A., Anan’yeva L.P. et al. Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board. Pul’monologiya 2021; 31(4): 505–510. (in Russ.) DOI: 10.18093/0869-0189-2021-31-4-505-510
5. Wijsenbeek M., Kreuter M., Olson A., Fischer A., Bendstrup E., Wells C.D. et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019; 35(11): 2015–2024. DOI: 10.1080/03007995.2019.1647040
6. Chanda D., Otoupalova E., Smith S.R., Volckaert T., De Langhe S.P., Thannickal V.J. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med 2019; 65: 56–69. DOI: 10.1016/j.mam.2018.08.004
7. Flaherty K.R., Brown K.K., Wells A.U., Clerisme-Beaty E., Collard H.R., Cottin V. et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4: e000212
8. Avdeev S.N., Ananyeva L.P., Zhilyaev E.V., Zonova E.V., Klimenko A.A., Koneva O.A. et al. The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019). Sovremennaya revmatologiya 2020; 14(1): 125–128. (in Russ.) DOI: 10.14412/1996-7012-2020-1-125-128
9. Wong A.W., Ryerson C.J., Guler S.A. Progression of fibrosing interstitial lung disease. Respir Res 2020; 21(1): 32. DOI: 10.1186/s12931-020-1296-3
10. Fan L.L., Dishop M.K., Galambos C., Askin F.B., White F.V.,- Langston C. et al. Diffuse lung disease in biopsied children 2 to 18 years of age. Application of the chILD classification scheme. Ann Am Thorac Soc 2015; 12: 1498–1505. DOI: 10.1513/AnnalsATS.201501-064OC
11. Deterding R.R., DeBoer E.M., Cidon M.J., Cidon M.J., Robinson T.E., Warburton D., Young L.R. Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200: 1219–1227. DOI: 10.1164/rccm.201903-0544CI
12. Vece T.J., Young L.R. Update on diffuse lung disease in children. Chest 2016; 149 (3): 836–845. DOI: 10.1378/chest.15-1986
13. Kröner C., Reu S., Teusch V., Schams A,. Grimmelt A.C., Barker M. et al. Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients. Eur Respir J 2015; 46: 197–206. DOI: 10.1183/09031936.00129414
14. Doan M.L., Guillerman R.P., Dishop M.K., Nogee L.M., Langston C., Mallory G.B. et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63: 366–373. DOI: 10.1136/thx.2007.083766
15. Campo I., Zorzetto M., Mariani F., Kadija Z., Morbini P., Dore R. et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res 2014; 15–43. DOI: 10.1186/1465-9921-15-43
16. Cidon M., Bansal M., Hartl D. Pulmonary manifestations of rheumatologic diseases. Curr Opin Pediatr 2017; 29: 311–319. DOI: 10.1097/MOP.0000000000000496
17. Wolf M.S., Chadha A.D., Carroll C.M., Borinstein S.C., Young L.R. Unusual progression and subsequent improvement in cystic lung disease in a child with radiation-induced lung injury. Pediatr Radiol 2015; 45: 1086–1090. DOI: 10.1007/s00247-014-3223-6
18. Clement A., Nathan N., Epaud R., Fauroux B., Corvol H. Interstitial lung diseases in children. Orphanet J Rare Dis 2010; 5: 22. DOI: 10.1186/1750-1172-5-22
19. Braun S., Ferner M., Kronfeld K., Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol 2015; 50: 410–419. DOI: 10.1002/ppul.23133
20. Saddi V., Beggs S., Bennetts B., Harrison J., Hime N., Kapur N. et al. Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade’s experience. Orphanet J Rare Dis 2017; 12: 133. DOI: 10.1186/s13023-017-0637-x
21. Clement A. ERS Task Force. Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 2004; 24: 686–697. DOI: 10.1183/09031936.04.00089803
22. Clement A., Eber E. Interstitial lung diseases in infants and children. Eur Respir J 2008; 31: 658–666. DOI: 10.1183/09031936.00004707
23. Fan L.L., Deterding R.R., Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38(5): 369–378. DOI: 10.1002/ppul.20114
24. Gorkem S.B., Köse S., Lee E.Y., Do÷anay S., Coskun A.S., Köse M. Thoracic MRI evaluation of sarcoidosis in children. Pediatr Pulmonol 2017; 52(4): 494–499. DOI: 10.1002/ppul.23614
25. Kogan E.A., Kornev B.M., Popova E.N., Fomin V.V. Interstitial lung diseases. Practical guide. Edited by N.A. Mukhin. M: Litterra, 2007; 432 p. (in Russ.)
26. Ilkovich M.M. Disseminated lung diseases. GEOTAR-Media. 2011; 480 s. (in Russ.)
27. Morisset J., Johannson K.A., Vittinghoff E., Aravena C., Elicker B.M., Jones K.D. et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest 2017; 151 (3): 619–625. DOI: 10.1016/j.chest.2016.10.029
28. Fiddler C.A., Simler N., Thillai M., Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis — A single-centre experience. Clin Respir J 2019; 13(12): 791–794. DOI: 10.1111/crj.13086
29. Adegunsoye A., Oldham J.M., Perez E.R.F., Hamblin M., Patel N., Tener M. et al. Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res 2017; 3(3): 000162017. DOI: 10.1183/23120541.00016-2017
30. Popova E.N., Kornev B.M., Reznikova K.U., Kondarova O.V. Pathogenetic and clinical rationale for the use of N-acetylcysteine (Fluimicil) in idiopathic fibrosing alveolitis. Pul’monologiya 2005; 1: 34–41 (in Russ.).
31. Griese M. Pulmonary alveolar proteinosis: a comprehensive clinical perspective. Pediatrics 2017; 140 (2): e20170610. DOI: 10.1542/peds.2017-0610
32. Breuer O., Schultz A. Side effects of medications used to treat childhood interstitial lung disease. Paediatr Respir Rev 2018; 28: 68–79. DOI: 10.1016/j.prrv.2018.03.002
33. Maher T.M., Corte T.J., Fischer A., Kreuter M., Lederer D.J., Molina-Molina M. et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8(2): 147–157. DOI: 10.1016/S2213-2600(19)30341-8
34. Behr J., Prasse A., Kreuter M., Johow J., Rabe K.F., Bonella F. et al. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9(5): 476–486. DOI: 10.1016/S2213-2600(20)30554-3
35. Wells A.U., Flaherty K.R., Brown K.K., Yoshikazu I., Devaraj A., Richeldi L. et al.; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8(5): 453–460. DOI: 10.1016/S2213-2600(20)30036-9
36. Wollin L., Distler J.H.W., Redente E.F., Riches D.W.H., Stowasser S., Schlenker-Herce R. et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019; 54: 1900161. DOI: 10.1183/13993003.00161-2019
37. Richeldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U. et al. For the IMPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. DOI: 10.1056/NEJMoa1402584
38. Distler O., Highland K.B., Gahlemann M., Azuma A., Fischer A., Mayes M.D. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–2528. DOI: 10.1056/NEJMoa1903076
39. Flaherty K.R., Wells A.U., Cottin V., Devaraj A., Walsh S.L.F., Inoue Y. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727. DOI: 10.1056/NEJMoa1908681
40. European Medicines Agency. OFEV® (nintedanib): Summary of Product Characteristics. www.ema.europa.eu/documents/product-information/ofev-epar-product-information_en.pdf.
41. U.S. Food & Drug Administration. OFEV® (nintedanib): prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2020/205832s013lbl.pdf.
42. Deterding R., Griese M., Deutsch G., Warburton D., DeBoer E.M., Cunningham S. et al. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Res 2021; 7(2): 00805–2020. DOI: 10.1183/23120541.00805-2020
Review
For citations:
Lev N.S., Mizernitsky Yu.L. Modern principles and prospects for drug therapy of interstitial lung diseases in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(3):18-22. (In Russ.) https://doi.org/10.21508/1027-4065-2022-67-3-18-22
Views:
513
Email this article 